Christine Traxler, MD,  —

Basilea Pharmaceutica Ltd recently announced plans to expand the delivery system of the experimental antibiotic BAL30072 to include an inhaled form suitable for cystic fibrosis patients and those with bronchiectasis.  Both conditions are known for the presence of multi-drug resistant colonization of bacteria that can lead to respiratory…

A recent review entitled “Inhaled therapy in cystic fibrosis: agents, devices and regimens” published in the journal Breathe explored the increasing number of inhaled therapeutic options for patients with CF, and how innovations in these therapies are dramatically improving quality of life…

Several studies have recently been released looking at the use of dry mannitol powder in an inhalation device for the management of cystic fibrosis. One study, entitled “Optimising inhaled mannitol for cystic fibrosis in an adult population,” published in Breathe, explored the safety and…